Brought to you by 
Norgine gets rights to Tranzyme's GI candidate ulimorelin; deal terminated
26 Apr 2013
Executive Summary
Drug discovery firm Tranzyme Pharma Inc. has licensed specialty pharmaco Norgine BV exclusive rights to develop and commercialize injectable formulations of its ghrelin receptor agonist ulimorelin (TZP101) in Europe, Australia, New Zealand, the Middle East, South Africa, and North Africa.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Norgine gets rights to Tranzyme's GI candidate ulimorelin; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice